Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone801-584-3600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$772.60 million
Profitability
Miscellaneous
Employees2,400
OptionableOptionable
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics, Inc. (NASDAQ:MYGN) posted its earnings results on Tuesday, November, 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.30 by $0.13. The firm earned $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The business's quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.26 earnings per share. View Myriad Genetics' Earnings History.
When is Myriad Genetics' next earnings date?
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics updated its FY19 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.74. The company issued revenue guidance of $855-865 million, compared to the consensus revenue estimate of $895.07 million.Myriad Genetics also updated its FY 2019 guidance to $1.70-1.75 EPS.
What price target have analysts set for MYGN?
11 analysts have issued twelve-month target prices for Myriad Genetics' shares. Their predictions range from $21.00 to $54.00. On average, they anticipate Myriad Genetics' stock price to reach $40.2720 in the next year. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for Myriad Genetics.
What is the consensus analysts' recommendation for Myriad Genetics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.
Has Myriad Genetics been receiving favorable news coverage?
Media stories about MYGN stock have been trending somewhat negative this week, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myriad Genetics earned a news impact score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT) and Akers Biosciences (AKER).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
- Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
- Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
- Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
- Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.04%), Fox Run Management L.L.C. (0.03%), State of Alaska Department of Revenue (0.03%), CHICAGO TRUST Co NA (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which major investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Louisiana State Employees Retirement System. Company insiders that have sold Myriad Genetics company stock in the last year include Dennis Langer, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone and Richard M Marsh. View Insider Buying and Selling for Myriad Genetics.
Which major investors are buying Myriad Genetics stock?
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $29.67.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $2.22 billion and generates $772.60 million in revenue each year. The company earns $131.10 million in net income (profit) each year or $1.20 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
What is Myriad Genetics' official website?
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
